tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2021 Jan 11;9(1):E40.
doi: 10.3390/vaccines9010040.
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model
Wen-Chun Liu[SUP] 1 2 3 [/SUP], Raffael Nachbagauer[SUP] 1 4 [/SUP], Daniel Stadlbauer[SUP] 1 [/SUP], Shirin Strohmeier[SUP] 1 [/SUP], Alicia Sol?rzano[SUP] 1 [/SUP], Francesco Berlanda-Scorza[SUP] 5 6 [/SUP], Bruce L Innis[SUP] 3 [/SUP], Adolfo Garc?a-Sastre[SUP] 1 2 7 8 [/SUP], Peter Palese[SUP] 1 7 [/SUP], Florian Krammer[SUP] 1 [/SUP], Randy A Albrecht[SUP] 1 2 [/SUP]
Affiliations
Abstract
Epidemic or pandemic influenza can annually cause significant morbidity and mortality in humans. We developed novel chimeric hemagglutinin (cHA)-based universal influenza virus vaccines, which contain a conserved HA stalk domain from a 2009 pandemic H1N1 (pH1N1) strain combined with globular head domains from avian influenza A viruses. Our previous reports demonstrated that prime-boost sequential immunizations induced robust antibody responses directed toward the conserved HA stalk domain in ferrets. Herein, we further followed vaccinated animals for one year to compare the efficacy and durability of these vaccines in the preclinical ferret model of influenza. Although all cHA-based immunization regimens induced durable HA stalk-specific and heterosubtypic antibody responses in ferrets, sequential immunization with live-attenuated influenza virus vaccines (LAIV-LAIV) conferred the best protection against upper respiratory tract infection by a pH1N1 influenza A virus. The findings from this study suggest that our sequential immunization strategy for a cHA-based universal influenza virus vaccine provides durable protective humoral and cellular immunity against influenza virus infection.
Keywords: chimeric hemagglutinin; ferret; hemagglutinin stalk antibody; long-lived immunity; universal influenza virus vaccine.
. 2021 Jan 11;9(1):E40.
doi: 10.3390/vaccines9010040.
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model
Wen-Chun Liu[SUP] 1 2 3 [/SUP], Raffael Nachbagauer[SUP] 1 4 [/SUP], Daniel Stadlbauer[SUP] 1 [/SUP], Shirin Strohmeier[SUP] 1 [/SUP], Alicia Sol?rzano[SUP] 1 [/SUP], Francesco Berlanda-Scorza[SUP] 5 6 [/SUP], Bruce L Innis[SUP] 3 [/SUP], Adolfo Garc?a-Sastre[SUP] 1 2 7 8 [/SUP], Peter Palese[SUP] 1 7 [/SUP], Florian Krammer[SUP] 1 [/SUP], Randy A Albrecht[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33440898
- DOI: 10.3390/vaccines9010040
Abstract
Epidemic or pandemic influenza can annually cause significant morbidity and mortality in humans. We developed novel chimeric hemagglutinin (cHA)-based universal influenza virus vaccines, which contain a conserved HA stalk domain from a 2009 pandemic H1N1 (pH1N1) strain combined with globular head domains from avian influenza A viruses. Our previous reports demonstrated that prime-boost sequential immunizations induced robust antibody responses directed toward the conserved HA stalk domain in ferrets. Herein, we further followed vaccinated animals for one year to compare the efficacy and durability of these vaccines in the preclinical ferret model of influenza. Although all cHA-based immunization regimens induced durable HA stalk-specific and heterosubtypic antibody responses in ferrets, sequential immunization with live-attenuated influenza virus vaccines (LAIV-LAIV) conferred the best protection against upper respiratory tract infection by a pH1N1 influenza A virus. The findings from this study suggest that our sequential immunization strategy for a cHA-based universal influenza virus vaccine provides durable protective humoral and cellular immunity against influenza virus infection.
Keywords: chimeric hemagglutinin; ferret; hemagglutinin stalk antibody; long-lived immunity; universal influenza virus vaccine.